NTT-ELECTRONICS
NTT Electronics, a leading provider of advanced components for optical communications systems including coherent optics and digital signal processors (DSPs), contributes the Goldstone Network Operating Software (NOS *1) for disaggregated coherent transponders to the Telecom Infra Project’s NOS Software Project hosted by the Open Optical and Packet Transport project group. Launched in February 2016, TIP was started with the goal of accelerating the pace of innovation in the telecom industry.
Goldstone utilizes many existing open source components which have been developed in Open Compute Project (OCP *2) and Telecom Infra Project (TIP *3) including Open Network Linux (ONL *4), SONiC *5, Switch Abstraction Interface (SAI *6) and Transponder Abstraction Interface (TAI *7) to provide a full-fledged open source solution. ONL is used as the base operating system and provides a wide range of open network device support. On top of ONL, Kubernetes *8 is employed to enable containerized application management, which realizes flexible and modular software composition. SONiC/SAI is deployed as a fleet of containers when the target hardware comprises Ethernet switch ASIC, whereas TAI is used when the target hardware has coherent transponder components. Because of its modular architecture, Goldstone can be extended to support networking devices, which don’t have Ethernet ASIC, but may include conventional transponders, ROADMs or amplifiers in the future.
Goldstone was originally started as a prototype NOS for Edgecore’s Cassini Platform by the proposal from NTT Electronics. This has led to a production deployment by mixi in Japan.
More than five industry partners are using Goldstone for evaluation on the Cassini platform.
It is also being incorporated in Wistron’s Galileo platform.
The NOS is planned to be contributed to TIP Open Optical Packet Transport (OOPT *9) group as an open source project. Goldstone is planned to be part of a live running demonstration at the TIP Summit 2019.
Quote from mixi, Inc.
“As the first operator who deployed Goldstone in production, mixi welcomes the contribution of Goldstone by NTT Electronics to foster more collaboration among the open networking industry. Goldstone brought us huge flexibility and control over our DCI connectivity which is critical for our services” Tatsuma Murase, CTO, mixi, Inc.
Quote from Edgecore
“Edgecore is pleased to be working with NTT Electronics and the broader industry community to enable disaggregated solutions with open packet transponders that will provide broader optical technology choices for network operators.” George Tchaparian, President and CEO, Edgecore Networks
Quote from Wistron
“Wistron is excited to have Goldstone in the open networking industry. Goldstone will accelerate the adaptation of the open disaggregated networking model and we believe it will become a viable solution together with our latest Galileo platform.” Arthur Chang, Sr. Technical Director, Wistron
*1 Network Operating System (NOS) : Operating system for a network device such as a router, switch or firewall.
*2 Open Compute Project (OCP) : The Open Compute Project (OCP) is a collaborative community focused on redesigning hardware technology to efficiently support the growing demands on compute infrastructure. In 2011, Facebook shared its designs with the public and launched the Open Compute Project and incorporated the Open Compute Project Foundation along with Intel, Rackspace, Goldman Sachs and Andy Bechtolsheim. (Reference: OCP web site: https://www.opencompute.org/ )
*3 Telecom Infra Project (TIP) : The Telecom Infra Project (TIP) is a collaborative telecom community founded by Facebook and partners. Launched in February 2016, TIP was started with the goal of accelerating the pace of innovation in the telecom industry. TIP members include operators, suppliers, developers, integrators, startups, and other entities that have joined TIP to build new technologies and develop innovative approaches for deploying telecom network infrastructure. (Reference: TIP web site: https://telecominfraproject.com/ )
*4 Open Network Linux (ONL) : Open Network Linux(ONL) is an open-source, foundational platform software layer for next-generation, modular NOS architecture on open networking hardware. ONL is a part of the Open Compute Project and is a component in a growing number of commercial NOS stacks and open source projects like CoRD & Stratum. (Reference: ONL web site : http://opennetlinux.org/ )
*5 Software for Open Networking in the Cloud (SONiC) : Open source software developed by Microsoft, etc.. It dramatically enhances operations and management of network switches. (Reference: SONiC repository: http://azure.github.io/SONiC/ )
*6 Switch Abstraction Interface (SAI) : The Switch Abstraction Interface (SAI) defines the API to provide a vendor-independent way of controlling forwarding elements, such as a switching ASIC, an NPU or a software switch in a uniform manner. (Reference: SAI repository: https://github.com/opencomputeproject/SAI )
*7 Transponder Abstraction Interface (TAI) : The Transponder Abstraction Interface (TAI) is the open API to provide a vendor-independent way of controlling coherent optical components. TAI has been developed under TIP OOPT group and NTT is leading the development. https://www.ntt.co.jp/news2018/1810e/181016c.html
*8 Kubernetes : Kubernetes is a portable, extensible, open-source platform for managing containerized workloads and services. Google open-sourced the Kubernetes in 2014. (Reference: Kubernetes web site : https://kubernetes.io/ )
*9 Open Optical Packet Transport (OOPT) : The Open Optical & Packet Transport project group will define Dense Wavelength Division Multiplexing (DWDM) open packet transport architecture that triggers new innovation and avoids implementation lock-ins. Open DWDM systems include open line system & control, transponder & network management and packet-switch and router technologies. (Reference: TIP web site: https://telecominfraproject.com/oopt/ )
About NTT Electronics
NTT Electronics (NEL) has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond link systems, ROADM components and FTTH networks. For more information about NEL, visit https://www.ntt-electronics.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112006191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom